Pharmaqube journal
Review Article - (2025) Volume 1, Issue 1
Emerging Therapies in Anemia: From Iron Supplementation to Gene Editing
#Equally contribution
Received Date: Jun 28, 2025 / Accepted Date: Jul 19, 2025 / Published Date: Jul 29, 2025
Abstract
Anemia is induced by a heterogeneity of factors, such as bone marrow malfunction, chronic illnesses, genetic disorders, and nutritional inadequacies. It’s likely to affect more than 1.6 billion people across the world. Although traditional medicines like erythropoiesis-stimulating agents (ESAs) and iron supplements continue to be essential, newer strategies including hepcidin modulators, CRISPR-Cas9 gene editing, and Hypoxia inducible factor (HIF) stabilizers have emerged. In this study range of conventional and innovative therapeutic approaches is examined, together with their mechanisms, clinical developments, and potential future applications in the treatment of customized Anemia.
Keywords
Anemia, Erythropoiesis-Stimulating Agents (ESAs), Iron Supplementation, Hepcidin Modulators, Hypoxia-Inducible Factor (HIF) Stabilizers, CRISPR-Cas9 Gene Editing
Citation: Bhavani, B., Manisha, R.L., Sirvi, B., Perveen, N., Mamidolu, K., et al (2025). Emerging Therapies in Anemia: From Iron Supplementation to Gene Editing. J pharm qube, 1(1), 1-20.
Copyright: © 2025 Bhavani B. et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.